Leff Todd, Mathews Suresh T, Camp Heidi S
Department of Pathology and the Center for Integrative Metabolic and Endocrine Research, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.
Exp Diabesity Res. 2004 Apr-Jun;5(2):99-109. doi: 10.1080/15438600490451668.
Since its identification as the receptor for antidiabetic thiazolidinedione drugs, peroxisome proliferator-activated receptor-gamma (PPARgamma) has been the focus of pharmaceutical drug discovery programs directed toward finding better drugs for the treatment of diabetes, as well as the object of basic research aimed at understanding its role in the regulation of metabolism. We now understand a great deal about the crucial role that PPARgamma plays in adipocyte differentiation and development, and are rapidly gaining knowledge about the role of the receptor in the regulation of metabolism. However, many crucial aspects of the molecular mechanism by which modulation of PPARgamma activity affects insulin resistance and glucose homeostasis are still not clearly understood. Here the authors review the current status of PPARgamma research, with an emphasis on its role in the causes and treatment of type 2 diabetes.
自被鉴定为抗糖尿病噻唑烷二酮类药物的受体以来,过氧化物酶体增殖物激活受体γ(PPARγ)一直是旨在寻找更好的糖尿病治疗药物的药物研发项目的重点,也是旨在了解其在代谢调节中作用的基础研究对象。我们现在对PPARγ在脂肪细胞分化和发育中所起的关键作用有了很多了解,并且正在迅速获得关于该受体在代谢调节中作用的知识。然而,PPARγ活性调节影响胰岛素抵抗和葡萄糖稳态的分子机制的许多关键方面仍未得到清楚理解。在此,作者综述了PPARγ研究的现状,重点是其在2型糖尿病病因和治疗中的作用。